CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership between us and the screening services for drug discovery.
What Will You Learn?
Who Should Watch?
Post-Docs, Managers, Scientists, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Contract Research Labs and Technology Providers involved in Target Discovery, Disease Modeling, Functional Screening, High-Throughput Screening, Assay Development and Translational Research.
Dr. Shawn Shafer
Director of Advanced Genomics
Dr. Shawn Shafer has been with us for 7 years and currently serves as the Director of Advanced Genomics. His group oversees the development of molecular tools for genetic research and diagnostic applications with a particular focus on genome editing technologies such as CRISPR.
Hauke Cornils, PhD
Research Scientist In Vitro Pharmacology
Hauke Cornils is leading the CRISPR technology platform at Evotec. He has more than 9 years of academic and industrial research experience, including a PhD at the Friedrich-Miescher Institute for Biomedical Research in Basel, Switzerland and a Post-Doc at the Dana-Farber Cancer Institute in Boston, US. His interests focus on understanding signal transduction in health and disease using phenotypic and genomic approaches.
Research and disease areas